DHR · Danaher Corporation
$195.672026-07-21Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$67
-65.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($72 · $123) Analysts Range ($200 · $265) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $23.9B | — | 23.6% | 15.6% | $4.8B | −$5.5B | −$757MM | 7.3% | — | 6.8% | $70.1B | $6.70 | — |
| 2024.Q4 | $23.9B | 0.0% | 23.6% | 16.1% | $4.7B | −$126MM | $4.6B | 8.7% | — | 6.9% | $68.1B | $6.70 | — |
| 2025.Q1 | $23.9B | -0.1% | 23.2% | 16.4% | $4.6B | −$430MM | $4.2B | 8.4% | — | 6.7% | $71.1B | $5.48 | — |
| 2025.Q4 | $23.9B | 0.0% | 23.2% | 14.6% | $4.7B | $120MM | $4.9B | 8.7% | — | 6.7% | $71.0B | $5.48 | — |
| 2026.Q1 | $24.8B | 3.8% | 22.4% | 15.0% | $4.7B | $415MM | $5.1B | 7.9% | — | 6.7% | $70.4B | $5.19 | 25.1 |
| italics below = DCF projection · 10yr Rev CAGR: 5.1% |
| 2027.Q1 | $25.9B | +4.6% | 22.4% | 15.5% | $4.9B | −$652MM | $4.3B | 8.8% | $3.9B | 6.9% | $71.1B | $6.45 | 30.3 |
| 2028.Q1 | $27.6B | +6.3% | 22.2% | 16.0% | $5.1B | −$1.3B | $3.9B | 8.8% | $3.3B | 7.2% | $72.4B | $6.75 | 29.0 |
| 2029.Q1 | $29.3B | +6.5% | 21.5% | 16.5% | $5.3B | −$2.2B | $3.1B | 8.8% | $2.4B | 7.2% | $74.5B | $6.92 | 28.3 |
| 2030.Q1 | $31.0B | +5.6% | 23.8% | 17.0% | $6.1B | $0MM | $6.1B | 8.8% | $4.4B | 8.2% | $74.5B | $8.05 | 24.3 |
| 2031.Q1 | $32.6B | +5.3% | 23.8% | 17.5% | $6.4B | $0MM | $6.4B | 8.8% | $4.2B | 8.6% | $74.5B | $8.43 | 23.2 |
|
| Term. Yr+ | $42.5B | 4.1% | 21.3% | 20.0% | $7.2B | −$3.5B | $3.8B | 8.6% | $36.4B | 8.6% | — | — | — |
Active scenario IV: $67 (-65.7% vs market)